News

Alarum Technologies (NASDAQ: ALAR): Analyzing Earnings and Trends

Alarum Technologies (NASDAQ: ALAR): Analyzing Earnings and Trends

Alarum Technologies Earnings Release: What to Expect

Alarum Technologies (NASDAQ: ALAR) is gearing up to unveil its quarterly earnings report soon. This announcement brings anticipation from investors eager for insights into the company's financial performance and future outlook. Understanding key metrics will play a crucial role for shareholders and potential investors alike.

Understanding the Earnings Expectations

Analysts predict that Alarum Technologies will report earnings per share (EPS) of $0.02. This estimate reflects market sentiment and expectations, highlighting the importance of assessing both anticipated earnings and subsequent guidance provided during the release.

Recent Performance Overview

In the previous quarter, Alarum Technologies exceeded earnings expectations by $0.15, despite this positive performance, the stock saw a slight decline of 4.92% the following day. This denotes the complexity of market reactions, where sometimes positive earnings reports do not lead to a proportional rise in stock price.

Earnings History Summary

A brief look at previous quarters showcases the earnings trajectory:

  • Quarterly EPS Estimates and Actuals:
  • Q1 2025: Estimated $0.01 | Actual $0.159
  • Q4 2024: Estimated $0.02 | Actual $0.20
  • Q3 2024: Estimated $0.04 | Actual $0.20
  • Q2 2024: Estimated $0.31 | Actual $0.41

Alarum Technologies Stock Dynamics

As of the latest reports, shares of Alarum Technologies are trading at approximately $16.82. Over the last year, the stock price has increased by 31.64%, which is a positive indicator. Many long-term shareholders are likely optimistic leading into the soon-to-be released earnings report.

Expert Analysts' Insights

Market sentiments can significantly influence investment decisions. Alarum Technologies has received positive feedback from analysts, achieving a consensus rating of Buy. The average one-year price target is projected to be around $18.5, suggesting potential upside for investors.

Industry Comparisons: Peers Performance

Examining Alarum Technologies alongside competitors like Duos Technologies Group and Silvaco Group provides valuable context. Current analyst ratings favor a Buy stance for competitors, providing insights into market expectations:

  • Duos Technologies: Average price target of $11.0 with a Buy recommendation.
  • Silvaco Group: Average price target of $12.0, also with a Buy recommendation.
  • Intrusion: Neutral rating with an average price target of $5.17.

Financial Metrics and Performance

A summary of Alarum Technologies' financials reveals several important metrics:

  • Market Capitalization: The company’s market cap indicates relatively smaller size compared to its peers, often suggesting growth challenges.
  • Revenue Trends: Revenue reports show a decline of nearly 14.84%, a notable contrast to industry competitors who have shown growth.
  • Profitability Metrics: Despite challenges, Alarum boasts a net margin of 5.72%, indicating robust profitability in operations.
  • Return on Equity (ROE): The company has maintained a healthy ROE of 1.51%, demonstrating efficient use of equity capital.
  • Debt Management: With a low debt-to-equity ratio of 0.05, Alarum Technologies' financial health remains stable, minimizing reliance on debt.

Final Thoughts on Alarum Technologies

Alarum Technologies stands out as a SaaS provider, specializing in web data collection solutions. Its successful delivery of anonymous IP Proxy Network Services aids businesses in securing and efficiently gathering data from public online domains. Despite facing challenges in revenue growth compared to larger peers, Alarum continues to maintain a strong foothold in profitability.

Frequently Asked Questions

What is the expected EPS for Alarum Technologies?

The expected earnings per share (EPS) for Alarum Technologies is $0.02 for the upcoming earnings announcement.

How has the stock performed historically for Alarum Technologies?

Historically, Alarum has had fluctuations in its stock price after earnings announcements, with some quarters resulting in significant price changes.

What are analysts predicting for Alarum's stock?

Analysts have a consensus rating of Buy for Alarum Technologies, with a one-year price target averaging around $18.5.

What industry does Alarum Technologies operate within?

Alarum Technologies operates primarily in the software-as-a-service (SaaS) domain, providing web data collection solutions and services.

What is Alarum Technologies' approach to financial management?

Alarum Technologies maintains a low debt-to-equity ratio, which suggests prudent financial management and a healthier balance sheet compared to industry standards.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 8

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Growth of the Network API Market by 2030

Updated Category News Views 125

Network API Market Overview As technology evolves, the demand for Network APIs is accelerating, and projections show the market will grow from USD 1.96 billion to an impressive USD 6.13 billion by 2030, reflecting a compound annual growth rate (CAGR) of 25.7% during the forecast period. This surge signifies a shift in how businesses leverage APIs to enhance connectivity...

Continue Reading
Quebec City Real Estate Market Sees Strong Activity Surge

Updated Category News Views 179

Quebec City Real Estate Market Activity in August As summer comes to a close, the residential real estate market in Quebec City is experiencing notable activity, achieving the second highest sales levels in 25 years for this month. This trend highlights the remarkable resilience and ongoing demand in a market that continues to change. Sales Data Overview In August, the...

Continue Reading
Understanding Market Trends: Income Strategies with IQQQ ETF

Updated Category News Views 151

Navigating the Current Tech Market Dynamics This year, the Nasdaq Composite index has outperformed other major indices, showing a solid increase of more than 21%. This surge in technology stocks has, however, been volatile, with the index recently experiencing a dip of roughly 2%. Concerns around a potential bubble in artificial intelligence have contributed to this...

Continue Reading
Boussard & Gavaudan Holding Limited: Latest NAV Update

Updated Category News Views 272

Boussard & Gavaudan Holding Limited Overview Boussard & Gavaudan Holding Limited is a well-known closed-ended investment company recognized within the finance industry for its effective management strategies. This article provides recent updates on the company's net asset value (NAV) and market activities. Estimated NAV Information The Directors of Boussard & Gavaudan...

Continue Reading
Currency Insights: Dollar and Yen Dynamics Amid Changes

Updated Category News Views 153

Current Trends in Currency Markets The US dollar is maintaining its strength as holiday trading continues with low volumes, while US Treasury yields are gradually rising. Although the dollar remains resilient against various currencies, it has shown some weakness against the Japanese yen and Canadian dollar lately. Markets are keenly observing the impact of potential...

Continue Reading